( BioMed Central ) The histone de-acetylase inhibitor panobinostat is able to target and destroy triple negative breast cancer, reveals a new study published in BioMed Central's open-access journal Breast Cancer Research. Researchers from Tulane University Health Sciences Center have shown that panobinostat was able to destroy breast cancer cells and reduce tumor growth in mice.

Gov. Martin O’Malley joined the governors of Delaware and West Virginia in Baltimore on Friday to discuss how states have found biopharmaceutical research companies to be an important source of jobs, tax revenue and research spending. O’Malley took part in a clinical trials forum with Delaware Gov. Jack Markell and West Virginia Gov. Earl Ray [...]

There is great news for parents suffering the harrowing ordeal of their child needing a bone marrow transplant. The announcement came from Osiris Therapeutics Inc. (NASDAQ: OSIR) on Friday that Health Canada has approved its groundbreaking stem cell therapy Prochymal® (remestemcel-L). The drug can be used to treat children with acute graft-vs-host disease. (GvHD). The decision is a historic one ...